Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

66.7%

6 terminated/withdrawn out of 9 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

5(55.6%)

Phase 2

3(33.3%)

N/A

1(11.1%)

9Total

Phase 1(5)

Phase 2(3)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03851250Phase 1Terminated

A Study of MRx-4DP0004 in Asthma

Role: lead

NCT04193904Phase 1Terminated

A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer

Role: lead

NCT03637803Phase 1Terminated

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Role: lead

NCT05832775Phase 1Withdrawn

Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's

Role: lead

NCT05107427Phase 2Withdrawn

Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma

Role: lead

NCT03934827Phase 1Unknown

MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour

Role: collaborator

NCT03721107Phase 2Completed

A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

Role: lead

NCT04363372Phase 2Withdrawn

A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19

Role: lead

NCT02704728Not ApplicableCompleted

Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease

Role: lead

All 9 trials loaded